๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Beneficial drugs for liver diseases

โœ Scribed by Pablo Muriel; Yadira Rivera-Espinoza


Book ID
102293910
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
119 KB
Volume
28
Category
Article
ISSN
0260-437X

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Liver diseases are a major problem of worldwide proportions. However, the number of drugs actually used successfully in humans is very small. In this review some of the most promising/studied drugs utilized for liver diseases were chosen and analysed critically from the basic to the clinical point of view. Antiviral agents are not discussed because excellent reviews have appeared on this topic. The compounds/preparations described herein are, alphabetically: colchicine, corticosteroids, curcumin, glycyrrhizin, interferons (for their antifibrotic properties), Liv 52, nitric oxide, resveratrol, silymarin, sulfoadenosylmethionine, and thalidomide. Colchicine and corticosteroids have been studied extensively in animals and humans; most clinical studies suggest that these compounds are not useful in the treatment of liver diseases. Glycyrrhizin is an herbal medicine with several components that has interesting hepatoprotective properties in patients with subacute liver failure but deserves more prospective controlled trials. Interferon has shown interesting antifibrotic properties in animals and humans; prospective studies on their antifibrotic/fibrolytic activity are required. Curcumin, resveratrol and thalidomide are very attractive newly discovered protective and curative compounds on experimental hepatic diseases. Their mechanism of action is associated with the ability to downโ€regulate NFโ€__ฮบ__B and to decrease pronecrotic and profibrotic cytokines. Unfortunately, clinical studies are lacking. Sulfoadenosylmethionine and silymarin are also promising drugs utilized mainly in cholestasis but the benefits can be expanded if more controlled trials are performed. The future is to carry out controlled prospective doubleโ€blind multicenter studies with the newly discovered drugs with proven beneficial effects on animals. Fundamental hepatobiology should also be encouraged. Copyright ยฉ 2007 John Wiley & Sons, Ltd.


๐Ÿ“œ SIMILAR VOLUMES


Drugs and liver disease
โœ A.E. READ ๐Ÿ“‚ Article ๐Ÿ“… 1965 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 819 KB
Drug-induced liver disease
โœ Shivakumar Chitturi; Geoffrey C. Farrell ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› Springer ๐ŸŒ English โš– 258 KB
Management of drug-induced liver disease
โœ Gustavo Marino; Hyman J. Zimmerman; James H. Lewis ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› Springer ๐ŸŒ English โš– 622 KB